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This supplement is intended to focus on drug eluting 
devices. Devices (eg cardiovascular stents, drug delivery 
biopolymers and tissue engineering devices), their bio­
compatibility, and mechanisms of transport are included 
within the supplement’s scope.
Drug Target Insights aims to provide researchers working 
in this complex, quickly developing field with online, 
open access to highly relevant scholarly articles by leading 
international researchers. In a field where the literature 
is ever-expanding, researchers increasingly need access 
to up-to-date, high quality scholarly articles on areas of 
specific contemporary interest. This supplement aims to 
address this by presenting high-quality articles that allow 
readers to distinguish the signal from the noise. The editor 
in chief hopes that through this effort, practitioners and 
researchers will be aided in finding answers to some of the 
most complex and pressing issues of our time.
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CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES
The rapidly expanding panorama of prosthetic replace-ment and interventional procedures for cardiovas-cular disease demands significant research for the 
development of devices with optimized characteristics and 
performance to overcome the drawbacks of the existing 
strategies. Tissue engineering is a potent weapon in this sce-
nario, enabling the realization of sophisticated biocompatible 
devices interacting with the host tissues and influencing their 
behavior. The fabrication and design of “smart” biomaterials, 
able to sense and interact with the biological milieu, represent 
a cornerstone in tissue engineering and regenerative medi-
cine. This development has demolished the obsolete tenets of 
surgery implying reconstructing organs or part of them with 
artificial materials. The deeper understanding achieved by 
modern research has highlighted the limitations and the bio-
logical and clinical drawbacks of the long-term coexistence of 
a foreign material in the body, especially in the cardiovascular 
system.1 The need to respect the physiological reparative and 
remodeling processes normally occurring in nature progres-
sively achieved significance in the current research,2,3 demon-
strating the necessity to accompany the body’s physiological 
responses and the activities of tissue regeneration rather than 
pretending to replace them with “plastic” surrogates. This 
attention to the biology of regeneration in tissue engineering 
and to micro-environmental conditions at the tissue and cel-
lular levels is expressed in the articles of this special issue of 
Drug Target Insights. Interesting and sophisticated approaches 
are proposed in this context, entailing the use of drug-delivery 
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devices that release tailored compounds to target specific 
aspects of diseases or complications. In this issue, Dr Rapetto 
and colleagues extensively reviewed the role of gentamicin-
impregnated collagen sponges (GICSs) in preventing sternal 
wound infection. The use of these delivery devices allows for 
topical delivery of high antibiotic concentrations to the wound, 
reducing the complications associated with gentamycin toxic-
ity.4 On the other side, alternative use of smart biopolymers 
able to release anticoagulant agents, such as heparin, to avoid 
early vascular graft thrombosis and failure will be presented 
and discussed in the same issue of the Journal.5 These are not 
the only applications in this field, as demonstrated by other 
papers in this issue. Indeed, at the experimental level, sev-
eral research efforts have been engaged in designing scaf-
fold-releasing factors, drugs or cytokines to improve tissue 
regeneration or stem cell recruitment, or to overcome pros-
thesis-related issues.6 The possibility to tailor a bioresorbable 
scaffold in order to create a microenvironment able to boost 
or guide tissue regeneration is an exciting area of investiga-
tion.7,8 Additionally, drug-releasing devices might also allow 
avoidance or treatment of some of the drawbacks related to 
prosthetic replacement of cardiovascular structures.5,6
In the field of interventional cardiology there is a wide-
spread use of drug-releasing stents, in particular of steroids or 
antiproliferative agents in order to prevent neointimal hyper-
plasia. Interestingly, the concept of paracrine or local release of 
molecules with modulatory or homeostatic action is not new in 
biology. Endothelium-mediated release of growth factors and 
regulatory molecules is a well-accepted natural mechanism to 
locally and remotely control or respond to a variety of physiologi-
cal or pathological conditions, and different parts of the vascular 
tree might behave differently according to their biological needs. 
This concept has important ramifications also in the clinical 
side, especially when treating cardiovascular structures. Release 
of drug from coronary stents (drug-eluting stents, DES) able to 
influence or modify endothelial homeostasis and function is an 
example. More interestingly, the use of autologous non-artifi-
cial conduits in coronary artery bypass graft (CABG) surgery 
might be considered another intriguing system of “natural” drug 
delivery device. CABG might be performed using autologous 
saphenous vein or internal thoracic artery (ITA or mammary 
artery), two conduits with profoundly different biological fea-
tures and structure. There is a general consensus on the acceler-
ated degeneration of venous grafts after surgery, with extremely 
high incidence of failure and lower patency rates in comparison 
to arterial grafts. This difference in angiographic patency was 
shown to be associated with improved clinical outcomes and 
rates of ischemia-free survival in patients undergoing exclusive 
arterial revascularization, especially in case of subjects who pre-
viously developed in-stent restenosis.9 Construction of coronary 
graft through the use of arterial conduits, especially with inter-
nal thoracic artery (ITA), is therefore advocated as desirable to 
ensure long-term patency and optimal clinical outcomes.10,11
The biological mechanisms underlying the poorer out-
comes of venous grafts in respect to arterial ones are not well 
understood and still a matter of debate. Reduced production of 
nitric oxide has been claimed as a primary factor,12 implicated 
in venous graft failure in relation to established risk factors 
for atherosclerosis;13 also, differences in thrombin recep-
tor expression between arterial and venous grafts have been 
demonstrated,14 and deregulation of these receptors has been 
associated with in-stent restenosis.15 Nitric oxide production 
is not reduced in arterial grafts and particularly the ITA, even 
with severe atherosclerotic disease, and this is thought to be 
one of the factors in the superior outcome of these conduits.16 
Additionally, it has been shown that the structure of the ITA 
itself is able to better adapt to arterial pressures and its endo-
thelium responds to high flow rates with a higher amount of 
nitric oxide, providing superior reactivity to flow requirements 
in the coronary arteries when used as a graft in CABG.17 
On this basis, ITA might be considered as a “drug-
eluting” graft as it is able to release into the grafted myocar-
dium nitric oxide, providing important signaling to prevent 
graft failure and ameliorate cardiac function. Clearly, the 
biology underlying this process is far more complex and is not 
restricted to a single compound, but most probably involves 
a wide spectrum of molecules interacting to determine the 
biological effects seen both experimentally and clinically. 
Proteomics studies allow for a comprehensive analysis 
and identification of the complete protein pattern of a tissue 
or fluid,18,19 and some studies performed using this approach 
showed the presence in human arterial smooth muscle of small 
leucine-rich proteoglycans involved in collagen fibrillogen-
esis, and of some non-fibrillar collagens in combination with 
alterations of several other proteins. This has been considered 
as a marker of arterial stiffness and therefore increased risk of 
developing atherosclerosis.20 Structural proteomic studies on 
ITA tissue showed differential expression of proteins that are 
implicated in cytoskeleton activity regulation,21 in the migrative 
capacity of vascular smooth muscle cells, extracellular matrix 
composition, coagulation, apoptosis, and heat shock response.22 
Interestingly, a proteomic analysis of the secrete of ITA, known 
as secretome, demonstrated an increased production of gelsolin, 
vinculin, lamin A/C and phosphoglucomutase 5 by mammary 
arterial tissues. These proteins are also involved in the regulation 
of important intracellular mechanisms related to cell migration, 
ECM deposition and smooth muscle phenotype switching, 
which are crucial steps in atherosclerosis pathogenesis.23 The 
expression of specific groups of proteins in the ITA is claimed to 
be the basis of the relative protection of this vessel from the onset 
and progression of atherosclerosis, and subsequently of its ben-
eficial effects when is used as a graft for coronary artery in terms 
of recurrence of heart disease.22,23 From these studies, we might 
reliably speculate that when used in the context of CABG, the 
ITA exerts a “paracrine activity” liberating locally and within 
the blood stream factors that are able to maintain a positive 
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vascular homeostasis, thereby avoiding disease recurrence in 
the grafted coronary and permitting high patency rate of the 
bypass in the long term. Considering the significant difference 
in patency rate when conduits different from ITA are used, 
more complex mechanisms should be underlying ITA selective 
advantage in CABG. Use of proteomics and redox-proteomics 
approaches to simultaneously compare the protein profile of 
ITA, saphenous vein grafts and aorta, another tissue prone to 
atherosclerosis, has been advocated to better understand differ-
ences among the conduits. Also, these investigations might be 
extended to the secretomes of these conduits in order to have a 
paracrine correlate to the targets found in the respective tissues. 
Differential profiles of protein expression exclusively present in 
ITA tissues and secrete, but not in the other vessels, have been 
intriguingly discovered (Fig. 1) and the identification of these 
proteins would provide in the future precious information to 
elucidate reasons of ITA superiority in CABG. Moreover, the 
identification of these proteins would enable more significant 
clinical applications. The factors produced by the ITA, and con-
sidered at the basis of the maintenance of graft patency and pro-
tection from atherosclerosis recurrence, might constitute in the 
future “drugs” to be administered to patients or eluted in stents 
or delivery devices. Conversely, factors identified from saphe-
nous tissue, which are clinically associated to poor outcomes 
and failure of the grafts, might represent targets for design of 
specific compounds with inhibitory or blocking effects.
In the field of drug-eluting devices, a close observation 
and attention to the naturally occurring phenomena might 
provide us with a range of therapeutic options wider than 
any other drug currently used in DES or tissue engineering 
approaches. For example, the ITA naturally carries a regu-
lated set of factors, finely modulated and intertwined, which 
protects against atherosclerosis and can be therefore consid-
ered the best drug-eluting device available at the moment in 
cardiovascular disease. 
In conclusion, with the increase in life expectancy and in 
the morbidities related to chronic diseases, smarter weapons 
are required to control pathology. The exciting field of drug 
delivery devices might provide novel strategies and open new 
avenues in the treatment of cardiovascular disease. In this 
context, scientists might need to realize that the endogenous 
and physiologically-occurring release of paracrine factors by 
the native tissues might be a “system” to better understand 
and to target when constructing new drug-releasing devices.
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